help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by ANDREW MCIVOR, R.
Right arrow Articles by SEARS, M. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ANDREW MCIVOR, R.
Right arrow Articles by SEARS, M. R.

Am. J. Respir. Crit. Care Med., Volume 158, Number 3, September 1998, 924-930

Potential Masking Effects of Salmeterol on Airway Inflammation in Asthma

R. ANDREW MCIVOR, EMILIO PIZZICHINI, MARK O. TURNER, PATRICIA HUSSACK, FREDERICK E. HARGREAVE, and MALCOLM R. SEARS

Firestone Regional Chest and Allergy Unit, St. Joseph's Hospital-McMaster University, Hamilton, Ontario, Canada

We hypothesized that regular use of long-acting beta -agonists could delay recognition of ("mask") increasing airway inflammation. We studied steroid-sparing and "masking" effects of salmeterol versus placebo in 13 asthmatic individuals requiring >=  1,500 µg inhaled corticosteroid daily. Corticosteroid doses were reduced weekly until criteria were met for an exacerbation or the corticosteroid was fully withdrawn. Subjects were restabilized on their original dose of inhaled corticosteroid for 4 wk before crossover to the alternative treatment. Subjects maintained symptom and peak expiratory flow (PEF) diaries, and underwent weekly spirometric, methacholine challenge, sputum eosinophil, and serum eosinophil cationic protein (ECP) measurements. Mean corticosteroid dose was reduced by 87% during salmeterol treatment, versus 69% with placebo (p = 0.04). Sputum eosinophils increased before exacerbation despite stable symptoms, FEV1, and PEF. In the week before clinical exacerbation, sputum eosinophil counts were higher in the salmeterol-treatment arm (19.9 ± 29.8% [mean ± SD], versus placebo 9.3 ± 17.6%; p = 0.006). Five subjects showed > 10% sputum eosinophilia before exacerbation during salmeterol treatment, as compared with two receiving placebo. In this model, salmeterol controlled symptoms and lung function until inflammation became significantly more advanced. We conclude that the bronchodilating and symptom-relieving effects of salmeterol can mask increasing inflammation and delay awareness of worsening asthma. McIvor RA, Pizzichini E, Turner MO, Hussack P, Hargreave FE, Sears MR. Potential masking effects of salmeterol on airway inflammation in asthma.




This article has been cited by other articles:


Home page
 Eur Respir JHome page
M. R. Sears, L-P. Boulet, M. Laviolette, J. M. Fitzgerald, T. R. Bai, A. Kaplan, N. Smiljanic-Georgijev, and J. S-M. Lee
Budesonide/formoterol maintenance and reliever therapy: impact on airway inflammation in asthma
Eur. Respir. J., May 1, 2008; 31(5): 982 - 989.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
H. Bisgaard, P. Le Roux, D. Bjamer, A. Dymek, J. H. Vermeulen, and C. Hultquist
Budesonide/Formoterol Maintenance Plus Reliever Therapy: A New Strategy in Pediatric Asthma
Chest, December 1, 2006; 130(6): 1733 - 1743.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
P. Ernst, A. McIvor, F. M. Ducharme, L.-P. Boulet, M. FitzGerald, K. R. Chapman, T. Bai, and for the Canadian Asthma Guideline Group
Safety and effectiveness of long-acting inhaled beta-agonist bronchodilators when taken with inhaled corticosteroids.
Ann Intern Med, November 7, 2006; 145(9): 692 - 694.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J. Hasford and J. C. Virchow
Excess mortality in patients with asthma on long-acting {beta}2-agonists.
Eur. Respir. J., November 1, 2006; 28(5): 900 - 902.
[Full Text] [PDF]

Home page
 ChestHome page
M. Humbert
The Right Tools at the Right Time
Chest, July 1, 2006; 130(1_suppl): 29S - 40S.
[Abstract] [Full Text] [PDF]

Home page
 ANN INTERN MEDHome page
S. R. Salpeter, N. S. Buckley, T. M. Ormiston, and E. E. Salpeter
Meta-Analysis: Effect of Long-Acting {beta}-Agonists on Severe Asthma Exacerbations and Asthma-Related Deaths
Ann Intern Med, June 20, 2006; 144(12): 904 - 912.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
J G Koopmans, R Lutter, H M Jansen, and J S van der Zee
Adding salmeterol to an inhaled corticosteroid: long term effects on bronchial inflammation in asthma
Thorax, April 1, 2006; 61(4): 306 - 313.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. E. Wechsler, E. Lehman, S. C. Lazarus, R. F. Lemanske Jr., H. A. Boushey, A. Deykin, J. V. Fahy, C. A. Sorkness, V. M. Chinchilli, T. J. Craig, et al.
beta-Adrenergic Receptor Polymorphisms and Response to Salmeterol
Am. J. Respir. Crit. Care Med., March 1, 2006; 173(5): 519 - 526.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. P. Currie, D. K. C. Lee, and P. Srivastava
Long-Acting Bronchodilator or Leukotriene Modifier as Add-on Therapy to Inhaled Corticosteroids in Persistent Asthma?
Chest, October 1, 2005; 128(4): 2954 - 2962.
[Abstract] [Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
H W. Kelly
What Is New with the {beta}2-Agonists: Issues in the Management of Asthma
Ann. Pharmacother., May 1, 2005; 39(5): 931 - 938.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
P. M. O'Byrne, H. Bisgaard, P. P. Godard, M. Pistolesi, M. Palmqvist, Y. Zhu, T. Ekstrom, and E. D. Bateman
Budesonide/Formoterol Combination Therapy as Both Maintenance and Reliever Medication in Asthma
Am. J. Respir. Crit. Care Med., January 15, 2005; 171(2): 129 - 136.
[Abstract] [Full Text] [PDF]

Home page
 EDUCATION AND PRACTICEHome page
K. Parameswaran
Review: inhaled long acting {beta}2 agonists are effective and safe in stable chronic asthma
Arch. Dis. Child. Ed. Pract., December 1, 2004; 89(3): ep80 - ep80.
[Full Text] [PDF]

Home page
 Evid. Based Med.Home page
K. Parameswaran
Review: inhaled long acting {beta}2 agonists are effective and safe in stable chronic asthma
Evid. Based Med., September 1, 2004; 9(5): 139 - 139.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
R.A. Pauwels, M.R. Sears, M. Campbell, C. Villasante, S. Huang, A. Lindh, W. Petermann, M. Aubier, G. Schwabe, and T. Bengtsson
Formoterol as relief medication in asthma: a worldwide safety and effectiveness trial
Eur. Respir. J., November 1, 2003; 22(5): 787 - 794.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
M. Mann, B. Chowdhury, E. Sullivan, R. Nicklas, R. Anthracite, and R. J. Meyer
Serious Asthma Exacerbations in Asthmatics Treated With High-Dose Formoterol
Chest, July 1, 2003; 124(1): 70 - 74.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
M.M.M. Pizzichini
Is sputum eosinophilia a good or poor predictor of benefit from inhaled corticosteroid therapy in asthma?
Eur. Respir. J., December 1, 2002; 20(6): 1359 - 1361.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
N. J. Vanacker, E. Palmans, R. A. Pauwels, and J. C. Kips
Effect of Combining Salmeterol and Fluticasone on the Progression of Airway Remodeling
Am. J. Respir. Crit. Care Med., October 15, 2002; 166(8): 1128 - 1134.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
E. Bacci, A. Di Franco, M.L. Bartoli, S. Carnevali, S. Cianchetti, F.L. Dente, D. Giannini, B. Vagaggini, L. Ruocco, and P.L. Paggiaro
Comparison of anti-inflammatory and clinical effects of beclomethasone dipropionate and salmeterol in moderate asthma
Eur. Respir. J., July 1, 2002; 20(1): 66 - 72.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
Leader of the Working Group:, J.C. Kips, Members of the Working Group:, M.D. Inman, L. Jayaram, E.H. Bel, K. Parameswaran, M.M.M. Pizzichini, I.D. Pavord, R. Djukanovic, et al.
The use of induced sputum in clinical trials
Eur. Respir. J., July 1, 2002; 20(37_suppl): 47S - 50s.
[Full Text] [PDF]

Home page
 ChestHome page
B. J. Lipworth and C. M. Jackson
Bronchodilator Reversibility to Albuterol Predicts Bronchodilator Response to Salmeterol
Chest, April 1, 2002; 121(4): 1382 - 1382.
[Full Text] [PDF]

Home page
 ChestHome page
S. Shrewsbury, S. Pyke, and M. R. Sears
MIASMA : Asthma Exacerbation Reduction With Salmeterol
Chest, March 1, 2002; 121(3): 1002 - 1003.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
C.P. van Schayck, I.D. Bijl-Hofland, S.G.M. Cloosterman, H.T.M. Folgering, F.J.J. van der Elshout, and C. Van Weel
Potential masking effect on dyspnoea perception by short- and long-acting {beta}2-agonists in asthma
Eur. Respir. J., February 1, 2002; 19(2): 240 - 245.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS and R. A. PAUWELS
Long-acting Inhaled beta 2-Agonist Therapy in Asthma
Am. J. Respir. Crit. Care Med., September 15, 2001; 164(6): 923 - 932.
[Full Text] [PDF]

Home page
 Eur Respir JHome page
H.J. van der Woude and R. Aalbers
Unaltered perception of dyspnoea during treatment with long-acting {beta}2-agonists
Eur. Respir. J., August 1, 2001; 18(2): 269 - 271.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
B. E. ORSIDA, C. WARD, X. LI, R. BISH, J. W. WILSON, F. THIEN, and E. H. WALTERS
Effect of a Long-acting {beta}2-Agonist over Three Months on Airway Wall Vascular Remodeling in Asthma
Am. J. Respir. Crit. Care Med., July 1, 2001; 164(1): 117 - 121.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. C. Lazarus, H. A. Boushey, J. V. Fahy, V. M. Chinchilli, R. F. Lemanske Jr, C. A. Sorkness, M. Kraft, J. E. Fish, S. P. Peters, T. Craig, et al.
Long-Acting {beta}2-Agonist Monotherapy vs Continued Therapy With Inhaled Corticosteroids in Patients With Persistent Asthma: A Randomized Controlled Trial
JAMA, May 23, 2001; 285(20): 2583 - 2593.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
R. F. Lemanske Jr, C. A. Sorkness, E. A. Mauger, S. C. Lazarus, H. A. Boushey, J. V. Fahy, J. M. Drazen, V. M. Chinchilli, T. Craig, J. E. Fish, et al.
Inhaled Corticosteroid Reduction and Elimination in Patients With Persistent Asthma Receiving Salmeterol: A Randomized Controlled Trial
JAMA, May 23, 2001; 285(20): 2594 - 2603.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
S. T. Holgate
Therapeutic Options for Persistent Asthma
JAMA, May 23, 2001; 285(20): 2637 - 2639.
[Full Text] [PDF]

Home page
 ChestHome page
M. R. Sears
Deleterious Effects of Inhaled {beta}-Agonists : Short-Acting and Long-Acting Agents Differ
Chest, May 1, 2001; 119(5): 1297 - 1299.
[Full Text] [PDF]

Home page
 ChestHome page
S. G. M. Cloosterman, I. D. Bijl-Hofland, C. L. A. van Herwaarden, R. P. Akkermans, F. J. J. van den Elshout, H. T. M. Folgering, and C. P. van Schayck
A Placebo-Controlled Clinical Trial of Regular Monotherapy With Short-Acting and Long-Acting {beta}2-Agonists in Allergic Asthmatic Patients
Chest, May 1, 2001; 119(5): 1306 - 1315.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
A. M. Wilson, O. J. Dempsey, E. J. Sims, and B. J. Lipworth
Evaluation of Salmeterol or Montelukast as Second-Line Therapy for Asthma Not Controlled With Inhaled Corticosteroids
Chest, April 1, 2001; 119(4): 1021 - 1026.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
I. Aziz, A. M. Wilson, and B. J. Lipworth
Effects of Once-Daily Formoterol and Budesonide Given Alone or in Combination on Surrogate Inflammatory Markers in Asthmatic Adults
Chest, October 1, 2000; 118(4): 1049 - 1058.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. C. KIPS, B. J. O'CONNOR, M. D. INMAN, K. SVENSSON, R. A. PAUWELS, and P. M. O'BYRNE
A Long-term Study of the Antiinflammatory Effect of Low-dose Budesonide Plus Formoterol versus High-dose Budesonide in Asthma
Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): 996 - 1001.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. P. ANDERSON
Interactions between Corticosteroids and beta -Adrenergic Agonists in Asthma Disease Induction, Progression, and Exacerbation
Am. J. Respir. Crit. Care Med., March 1, 2000; 161(3): S188 - 196.
[Full Text] [PDF]

Home page
 ChestHome page
B. J. Lipworth and J. N. Baraniuk
Use of Fluticasone in Asthma
Chest, February 1, 2000; 117(2): 611 - 613.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
X. LI, C. WARD, F. THIEN, R. BISH, T. BAMFORD, X. BAO, M. BAILEY, J. W. WILSON, and E. HAYDN WALTERS
An Antiinflammatory Effect of Salmeterol, a Long-acting beta 2 Agonist, Assessed in Airway Biopsies and Bronchoalveolar Lavage in Asthma
Am. J. Respir. Crit. Care Med., November 1, 1999; 160(5): 1493 - 1499.
[Abstract] [Full Text]

Home page
 CMAJHome page
{beta}2-Agonists
Can. Med. Assoc. J., November 1, 1999; 161(90111): s28 - 31.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
A. E. TATTERSFIELD, D. S. POSTMA, P. J. BARNES, K. SVENSSON, C.-A. BAUER, P. M. O'BYRNE, C.-G. LÖFDAHL, R. A. PAUWELS, and A. ULLMAN
Exacerbations of Asthma . A Descriptive Study of 425 Severe Exacerbations
Am. J. Respir. Crit. Care Med., August 1, 1999; 160(2): 594 - 599.
[Abstract] [Full Text]

Home page
 ChestHome page
I. Aziz and B. J. Lipworth
A Bolus of Inhaled Budesonide Rapidly Reverses Airway Subsensitivity and {beta}2-Adrenoceptor Down-regulation After Regular Inhaled Formoterol
Chest, March 1, 1999; 115(3): 623 - 628.
[Abstract] [Full Text] [PDF]

Home page
 BMJHome page
B. J Lipworth
Fortnightly review: Modern drug treatment of chronic asthma
BMJ, February 6, 1999; 318(7180): 380 - 384.
[Full Text]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 1998 American Thoracic Society